BIOMAT Database Logo BIOMAT Database Logo

Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects. 1986

J A Barone, and J J Raia, and D B Levy

Dihydroergotamine(DHE)-heparin combination offers a unique treatment modality for the prevention of deep vein thrombosis. The combination appears to affect all 3 limbs of Virchow's triad: hypercoagulability, venous stasis, and endothelial damage. In most efficacy studies, data indicated that the combination of DHE 0.5 mg and heparin 5000 IU was superior to low-dose heparin alone. Even when the efficacy of DHE-heparin was the same as that of heparin alone, the use of the combination allowed for a decrease in the heparin dose required.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008012 Lidocaine A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE. Lignocaine,2-(Diethylamino)-N-(2,6-Dimethylphenyl)Acetamide,2-2EtN-2MePhAcN,Dalcaine,Lidocaine Carbonate,Lidocaine Carbonate (2:1),Lidocaine Hydrocarbonate,Lidocaine Hydrochloride,Lidocaine Monoacetate,Lidocaine Monohydrochloride,Lidocaine Monohydrochloride, Monohydrate,Lidocaine Sulfate (1:1),Octocaine,Xylesthesin,Xylocaine,Xylocitin,Xyloneural
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D004087 Dihydroergotamine A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS. Agit,Angionorm,Clavigrenin,D-Tamin Retard L.U.T.,D.H.E. 45,DET MS,DHE-45,DHE-Puren,DHE-Ratiopharm,Dihydergot,Dihydroergotamin AL,Dihydroergotamine Mesylate,Dihydroergotamine Methanesulfonate,Dihydroergotamine-Sandoz,Dihytamin,Erganton,Ergomimet,Ergont,Ergotam Von Ct,Ikaran,Migranal,Orstanorm,Seglor,Tamik,Verladyn,D Tamin Retard L.U.T.,DHE 45,DHE Puren,DHE Ratiopharm,DHE45,Dihydroergotamine Sandoz,Mesylate, Dihydroergotamine,Methanesulfonate, Dihydroergotamine,Von Ct, Ergotam
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004727 Endothelium A layer of epithelium that lines the heart, blood vessels (ENDOTHELIUM, VASCULAR), lymph vessels (ENDOTHELIUM, LYMPHATIC), and the serous cavities of the body. Endotheliums
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013924 Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS). Phlegmasia Alba Dolens,Dolens, Phlegmasia Alba,Thrombophlebitides

Related Publications

J A Barone, and J J Raia, and D B Levy
The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination.
July 1983, Thrombosis research,
J A Barone, and J J Raia, and D B Levy
Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects.
January 1984, Pharmacotherapy,
J A Barone, and J J Raia, and D B Levy
Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine.
February 1981, Thrombosis and haemostasis,
J A Barone, and J J Raia, and D B Levy
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
April 1999, Journal of clinical pharmacy and therapeutics,
J A Barone, and J J Raia, and D B Levy
[Glucocorticosteroids: mechanism of action, pharmacological effects, pharmacokinetics and adverse effects].
January 1994, Otolaryngologia polska = The Polish otolaryngology,
J A Barone, and J J Raia, and D B Levy
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
October 1995, Chest,
J A Barone, and J J Raia, and D B Levy
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
October 1992, Chest,
J A Barone, and J J Raia, and D B Levy
Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma.
January 1985, Pharmacotherapy,
J A Barone, and J J Raia, and D B Levy
Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action.
January 1982, Pharmacotherapy,
J A Barone, and J J Raia, and D B Levy
Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications.
June 2013, Obstetrical & gynecological survey,
Copied contents to your clipboard!